Enanta Pharmaceuticals stock fell 2.78 percent on October 5
Enanta Pharmaceuticals stock dropped by 2.78% on October 5, trading at USD 12.60. This decline follows the company's weak fiscal third-quarter results, which showed revenue of USD 14.36 million, below consensus estimates, and a consolidated net loss of USD 19.5 million. Despite the financial performance, analysts maintain a "Moderate Buy" consensus with an average price target of USD 19.00, valuing the company based on its clinical pipeline progress rather than current profitability.
Enanta Pharmaceuticals Inc (9EP.SG) Analyst insights, Price targets and Recommendations
This article provides analyst insights, price targets, and recommendations for Enanta Pharmaceuticals Inc (9EP.SG). It lists several reiterations of "Buy" ratings from HC Wainwright & Co., an initiation of "Overweight" from JP Morgan, and a "Buy" maintenance from WestPark Capital, spanning from late 2025 to late 2026. The stock was trading at 11.20 EUR, down 1.75% at the close on October 5th.
Enanta Pharmaceuticals stock gains 4.48 percent to EUR 11.65
Enanta Pharmaceuticals (ENTA) saw its stock price rise by 4.48% to EUR 11.65 at Lang & Schwarz on September 30, 2026, despite missing fiscal Q3 revenue estimates by $2.40 million. Analysts maintain a "Moderate Buy" consensus with an average 12-month target of $21.00, significantly above the current price. The company's focus on RSV programs and royalty income are key factors for investors, while the stock remains below its yearly high.
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals (NASDAQ: ENTA) announced its participation in two upcoming investor conferences in September. Jay R. Luly, Ph.D., President and CEO, will present at the H.C. Wainwright Global Investment Conference and the Morgan Stanley Global Healthcare Conference. This will allow investors to hear updates on the company's progress and pipeline.
Enanta Pharmaceuticals stock falls 1.25 percent to USD 11.85
Enanta Pharmaceuticals stock declined by 1.25% to USD 11.85 on September 25, 2026, after its fiscal Q3 revenue of USD 14.36 million missed analyst estimates. Despite the revenue miss, analysts maintain a "Moderate Buy" consensus with an average 12-month price target of USD 21.00, suggesting a significant upside. The company's pipeline, particularly RSV treatments, is highlighted as a future catalyst.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month target price of $21.00. Despite recent financial results falling short of expectations, institutional investors maintain high ownership, holding nearly 95% of ENTA shares. The company's stock recently opened at $12.00, having a market cap of $349.50 million.
Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Enanta Pharmaceuticals (NASDAQ: ENTA) following positive Phase 3 trial results from Celldex for a competing chronic spontaneous urticaria treatment. Enanta's oral KIT inhibitor, EDP-978, is seen as a significant near-term catalyst, with Phase 1 data expected in Q4 2026. This comes as Enanta recently reported fiscal third-quarter results below analyst expectations, primarily due to decreased royalty revenue.
Enanta Pharmaceuticals stock trades at USD 12.11
Enanta Pharmaceuticals (ENTA) stock traded at USD 12.11 on September 22, 2026, marking a 0.74 percent decline. The company's investment case is closely tied to its research programs and potential commercial milestones within the small-cap biotechnology sector. The market capitalization figure for Prothena Corporation plc was mistakenly included on the source page but is not relevant to Enanta.
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals, a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2026: the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Management representatives will hold fireside chats at both events, with live webcasts and replays available on the company's website. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases, with existing revenue from its hepatitis C drug, glecaprevir (MAVYRET/MAVIRET), developed with AbbVie.
Enanta Pharmaceuticals to Participate in September 2026 Investor Conferences
Enanta Pharmaceuticals, Inc. announced that its management will participate in two investor conferences in September 2026: the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts and replays of these fireside chats will be available on the "Events and Presentations" section of Enanta's investor website. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S
Deep Track Capital, LP significantly reduced its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by selling over 512,000 shares, decreasing its position by 26.20%. This move reflects a reassessment of Enanta, which is currently deemed "Significantly Overvalued" with a GF Value of $7.98 against a trading price of $13.14. The biotechnology company faces financial challenges, weak profitability, and growth metrics, prompting caution from institutional investors despite some recent price momentum.
Enanta Pharmaceuticals (ENTA) trims losses, funds pipeline into 2029
Enanta Pharmaceuticals (ENTA) reported narrowed net losses and expects its current cash and retained royalties to fund operations into fiscal 2029. The company's Q2 2026 royalty revenue decreased due to lower HCV sales, but R&D and general administrative expenses also declined. Enanta is advancing its RSV and immunology pipeline, including initiating registrational and pediatric clinical trials for zelicapavir and progressing other immunology programs.
Enanta Pharmaceuticals (Nasdaq:ENTA) - Stock Analysis
This Simply Wall St analysis provides a detailed overview of Enanta Pharmaceuticals (ENTA), a biotechnology company specializing in small molecule drugs. The report covers the company's valuation, future growth prospects (revenue forecast to grow 21.99% annually), past performance, financial health, and dividend policy, noting it is currently unprofitable but analysts expect stock price growth. It also includes market data such as share price history, volatility, and comparison against industry and market returns.
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Enanta Pharmaceuticals (ENTA) experienced a 2.1% stock slip after reporting a Q3 loss with basic earnings per share at -$0.67 and a wider net loss of $19.50 million. While loss per share improved year-over-year, revenue declined from $18.31 million to $14.36 million, raising concerns about commercial cash flow and the company's ability to support its R&D pipeline amid continued losses and shareholder dilution. Investors are advised to consider the financing and execution risks associated with the company's early to mid-stage portfolio.
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Enanta Pharmaceuticals Inc. reported a fiscal third-quarter loss of $19.5 million, or 67 cents per share. The biotechnology company generated $14.4 million in revenue during the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Enanta Pharma misses Q3 estimates on lower royalty revenue
Enanta Pharmaceuticals missed its Q3 earnings and revenue estimates, reporting an adjusted EPS of -$0.67 against an expected -$0.50, and revenue of $14.4 million, short of the $17.4 million forecast. The shortfall was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with a Phase 2b pediatric trial underway for zelicapavir and a registrational trial expected to start in Q4 2026.
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals announced its financial results for the fiscal third quarter ended June 30, 2026. The report details the company's financial performance during this period.
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline
Enanta Pharmaceuticals reported a net loss of $19.5 million for Q3 FY26, with revenue dropping 21% year-over-year to $14.4 million, missing analyst estimates. Despite financial setbacks, the company advanced its RSV pipeline, initiating the LOTUS pediatric trial and preparing for the RESOLVE adult trial. Enanta maintains a strong cash position of $211.5 million, providing financial runway into fiscal 2029.
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a quarterly loss of $0.67 per share, missing analyst estimates by $0.16. The biotechnology company also showed negative return on equity and net margin. Despite the earnings miss, the stock rose 0.3% during Monday trading, and institutional investors hold a significant portion of the company's shares.
Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M
Enanta Pharmaceuticals reported a Q3 fiscal year loss of $19.5 million on revenue of $14.4 million, with $211.5 million in cash and marketable securities. The company expects current resources to fund operations into fiscal 2029 and highlighted progress in its virology and immunology programs, including a Phase 2b pediatric trial for zelicapavir and a Phase 1 readout for EDP-978 in Q4 2026.
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss
Enanta Pharmaceuticals reported a 21.6% decline in fiscal Q3 2026 revenue to $14.4 million due to lower MAVYRET/MAVIRET royalties. Despite narrowed operating losses from reduced clinical trial spending, the net loss widened to $19.5 million because of increased royalty-related interest expenses. The company holds $211.5 million in cash and marketable securities, expected to fund operations through fiscal 2029, and is focusing on key clinical trials and managing patent litigation risks.
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com
Enanta Pharmaceuticals reported third-quarter results that fell short of analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, missing estimates of -$0.50 and $17.4 million, respectively. This underperformance was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with topline data for a Phase 2b pediatric trial expected in 2027 and a registrational Phase 2b/3 trial for high-risk adults on track for Q4 2026.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) reported a Q3 loss of $0.67 per share, significantly missing the Zacks Consensus Estimate of a $0.37 loss, and its revenues of $14.36 million also fell short of expectations. Despite exceeding EPS estimates three times in the last four quarters, the company's shares have declined 12.7% year-to-date. Investors are now looking to management's commentary and future earnings outlook, with the stock currently holding a Zacks Rank #3 (Hold).
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals reported its fiscal third-quarter results for the period ended June 30, 2026, highlighting progress in its RSV and immunology programs. The company initiated dosing in a Phase 2b pediatric trial for Zelicapavir, with topline data expected in 2027, and is on track to begin a registrational Phase 2b/3 trial for high-risk adults. Total revenue was $14.4 million, primarily from MAVYRET®/MAVIRET® royalties, and the company maintains a strong cash position of $211.5 million, projected to fund operations into fiscal 2029.
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharmaceuticals Inc is projected to report a loss of 51 cents per share, according to a Reuters earnings preview sourced from Refinitiv. The article provides this key financial forecast ahead of the company's earnings announcement.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $20.29, significantly higher than its current share price of $13.22. The company, which specializes in antiviral drug discovery, saw substantial institutional ownership at 94.99% and slightly beat quarterly earnings estimates, though it remains unprofitable. Analysts anticipate a full-year loss of $1.79 per share for Enanta.
(ENTA) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), indicating a strong near-term sentiment potentially leading to a long-term positive bias. It highlights a significant 61.0:1 risk-reward setup targeting a 19.8% gain with minimal risk and outlines specific institutional trading strategies for different risk profiles. The analysis also includes multi-timeframe signal analysis, providing support and resistance levels for various time horizons.
ENTA|Enanta Pharmaceuticals Inc|Price:12.610|Chg%:-0.120
Enanta Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. Their pipeline includes treatments for RSV, inflammatory diseases, SARS-CoV-2, and Hepatitis B virus, with their discovered glecaprevir being part of an HCV treatment sold by AbbVie. The article provides an overview of the company, its financial data, and key executives.
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Enanta Pharmaceuticals Inc (ENTA), highlighting its current valuation score of 8.22 within the Pharmaceuticals industry. It details the company's P/E ratio, noting its current value of -4.91 relative to its recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Enanta Pharmaceuticals Inc (ENTA), highlighting that relevant business segment and regional profit contribution data has not yet been disclosed by the company. It does, however, show a United States revenue figure of $18.61 million with a 0.00% proportion, indicating incomplete reporting at the time of publication. The page also offers current stock quotes and basic financial overview links for ENTA.
ENTA|Enanta Pharmaceuticals Inc|Price:12.730|Chg%:-0.050
Enanta Pharmaceuticals Inc (ENTA) has a high growth potential and its fundamentals are stable, though its stock market performance has been weak recently. The company is engaged in developing small molecule drugs for virology and immunology, with clinical programs focused on RSV. Analysts have rated the stock as a "Buy" with a high price target, and institutional ownership is significant.
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170
Enanta Pharmaceuticals Inc. (ENTA) closed at $12.780, down 1.31%, with a market cap of $371.40 million. Analysts rate the stock as a "Buy" with a target price of $22.833, indicating a potential upside of 76.32%. The company specializes in clinical-stage biotechnology, focusing on small molecule drugs for virology and immunology, including treatments for RSV, SARS-CoV-2, and Hepatitis B virus.
Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) generated $65.32 million USD in revenue last year, primarily from its Small Molecule Drugs segment. This represents a slight decrease from the previous year's $67.64 million USD. The United States was the sole geographic contributor to its revenue.
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit.
This article discusses a patent dispute where Enanta Pharmaceuticals lost to Pfizer despite filing first, due to a single digit error in their provisional patent application. The Federal Circuit affirmed that Enanta's patent for a coronavirus protease inhibitor was invalid because the provisional application did not disclose the specific compound later found in Pfizer's Paxlovid. The case highlights the critical importance of meticulous detail and accuracy in provisional patent filings, especially in competitive and fast-moving fields.
Enanta Pharmaceuticals (9EP) Q2 2024 Earnings Report - Results, Call & Slides
Enanta Pharmaceuticals reported its Q2 2024 earnings with a mixed sentiment, missing EPS estimates by CHF0.11 with an actual EPS of -CHF1.20, but beating revenue estimates with CHF13.93M. The company highlighted advancements in its RSV and immunology programs, including progress in two Phase II studies and pipeline expansion, while also noting a decline in revenue and increased net loss. Enanta projects $125 million to $145 million in R&D expenses and expects its $300 million in cash to fund operations through Q3 2027.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article provides the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It describes the company's financial data available on TradingView, covering various financial metrics and market information. The content focuses on the specific financial ratio for the pharmaceutical company.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP
The article focuses on the enterprise value to EBIT forward ratio for Enanta Pharmaceuticals, Inc. (BX:9EP) as listed on the BX Swiss exchange. It highlights the financial metric's value, change, and percentage change over a specified period. The content appears to be a stub or a section of a larger financial data page on TradingView.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
The article provides financial data for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market status as closed with no trades. The document highlights the data sources and copyright information for the financial and reference data presented.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP
The article focuses on the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (DUS:9EP) as listed on the Dusseldorf Stock Exchange. It provides a financial overview, though no specific values are present, and highlights the company's listing within the Health Technology and Pharmaceuticals sector. The content appears to be a financial data page from TradingView.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP
This page on TradingView provides financial information for Enanta Pharmaceuticals, Inc. (SWB:9EP), focusing on its enterprise value to forward EBITDA. The content is primarily an outline for financial data and analysis tools available on the platform, without detailed numerical figures or analytical insights here.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP
This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Enanta Pharmaceuticals, Inc. (9EP) traded on the Dusseldorf Stock Exchange. It appears to be a financial data snippet from TradingView, offering a quick overview without detailed analysis or figures in this excerpt.
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about data sources and copyrights.
Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com
This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This page on TradingView.com focuses on the "Price to sales forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta Pharmaceuticals. The content primarily serves as a financial data point for investors and analysts.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market. The article also provides a brief overview of Enanta Pharmaceuticals, including its focus on antiviral and immunology drug discovery and development.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and ongoing developments, including its RSV clinical programs and patent dispute with Pfizer.
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry
This article is a statement of changes in beneficial ownership of securities for Enanta Pharmaceuticals, specifically pertaining to Director Vance Terry. It is a regulatory filing indicating transactions related to his holdings in the company.
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others
This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under "Others," suggesting a beneficial ownership report from a passive investor or another type of filer.
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP
This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financial data point presented on the TradingView platform.
